Novel carbazole inhibits phospho-STAT3 through induction of protein-tyrosine phosphatase PTPN6

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Aberrant activation of Signal Transducer and Activator of Transcription 3 (STAT3) is implicated in numerous human cancers.
• Phosphorylation of STAT3 at tyrosine 705 (Y705) is critical for its oncogenic function.
• Targeting STAT3 signaling presents a potential therapeutic strategy for cancer treatment.

Purpose of the Study:

• To investigate the efficacy of a synthesized carbazole derivative, Compound 12, as a STAT3 phosphorylation inhibitor.
• To evaluate the anti-cancer effects of Compound 12 in triple-negative breast cancer (TNBC) and lung cancer models.
• To elucidate the mechanism of action of Compound 12 in inhibiting STAT3 signaling.

Main Methods:

• In vitro studies using cancer cell lines with varying levels of phospho-STAT3 (Y705).
• In vivo studies using human TNBC (SUM149) and lung cancer (A549) xenograft models.
• Assessment of STAT3-mediated transcription, IL-6 induced STAT3 phosphorylation, apoptosis, tumor growth inhibition, and protein-tyrosine phosphatase PTPN6 expression.

Main Results:

• Compound 12 inhibited STAT3-mediated transcription and reduced IL-6 induced STAT3 phosphorylation in cancer cell lines.
• Compound 12 induced apoptosis in vitro and inhibited tumor growth in vivo in TNBC and lung cancer xenografts without observable toxicity.
• The inhibitory effects of Compound 12 on phospho-STAT3 were mediated by the upregulation of protein-tyrosine phosphatase PTPN6.

Conclusions:

• Compound 12 demonstrates potent anti-cancer activity against TNBC and other cancers with constitutive STAT3 signaling.
• Compound 12 acts by upregulating PTPN6, leading to inhibition of STAT3 phosphorylation.
• Compound 12 warrants further preclinical development as a potential chemotherapeutic agent.